Mitologics Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 6


  • Latest Deal Type
  • Accelerator/​Inc

  • Investors
  • 1

Mitologics General Information


Provider of biotechnological research services intended to detect mitochondrial injury. The company's services are primarily focused on predictive toxicology, tumor targeting, and mitochondrial targeting, enabling clients to compound screening on isolated mitochondria from healthy tissues and tumor cells.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Other Industries
Other Healthcare Services
Corporate Office
  • 102 Avenue Gaston Roussel
  • 93230 Romainville
  • France
+33 06 00 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mitologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Accelerator/Incubator 01-Mar-2009 Completed Generating Revenue
To view Mitologics’s complete valuation and funding history, request access »

Mitologics Patents

Mitologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20140350033-A1 Ant-ligands molecules and biological applications Active 30-May-2008 0000000000 0
US-9657031-B2 Ant-ligands molecules and biological applications Active 30-May-2008 0000000000 0
CA-2725220-A1 Pyrimidinones and pyrimidines derivates as ant-ligands molecules and biological applications Active 30-May-2008 0000000000
US-20110086865-A1 Ant-ligands molecules and biological applications Active 30-May-2008 0000000000 0
US-8809346-B2 Ant-ligands molecules and biological applications Active 30-May-2008 C07D495/04 0
To view Mitologics’s complete patent history, request access »

Mitologics Executive Team (3)

Name Title Board Seat
Annie Borgne-Sanchez Ph.D Co-Founder, Owner, Chief Executive Officer, Chief Scientific Officer & President
Mathieu Porceddu Co-Founder & Platform Manager
Nelly Buron Ph.D Co-Founder, Head of Research & Development & Study Manager
To view Mitologics’s complete executive team members history, request access »

Mitologics Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mitologics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Agoranov Accelerator/Incubator 000 0000 000000 0
To view Mitologics’s complete investors history, request access »

Mitologics FAQs

  • When was Mitologics founded?

    Mitologics was founded in 2009.

  • Who is the founder of Mitologics?

    Annie Borgne-Sanchez Ph.D, Mathieu Porceddu, and Nelly Buron Ph.D are the founders of Mitologics.

  • Who is the CEO of Mitologics?

    Annie Borgne-Sanchez Ph.D is the CEO of Mitologics.

  • Where is Mitologics headquartered?

    Mitologics is headquartered in Romainville, France.

  • What is the size of Mitologics?

    Mitologics has 6 total employees.

  • What industry is Mitologics in?

    Mitologics’s primary industry is Biotechnology.

  • Is Mitologics a private or public company?

    Mitologics is a Private company.

  • What is Mitologics’s current revenue?

    The current revenue for Mitologics is 000000.

  • Who are Mitologics’s investors?

    Agoranov has invested in Mitologics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »